Prof. Dolores J.
Cahill, Professor of Translational Science at UCD
School of Medicine, University College Dublin
Prof. Dr Dolores Cahill has over 25 years expertise
in high-throughput protein array, antibody array,
proteomics technology development, automation and
their biomedical applications, including in
biomarker discovery, diagnostics and personalized
medicine.
�
She is Professor of
Translational Science, School of Medicine and at the
Conway Institute at the University College Dublin (UCD)
(2005-present). With her research group &
collaborators, she has achieved key breakthroughs in
developing and demonstrating applications of high
throughput array technology in biological,
diagnostics & medical research.
�
Prof. Cahill pioneered
this research at the Max-Planck-Institute of
Molecular Genetics in Berlin, Germany (1996-2003)
and holds several granted international patents in
this vital field.
�
Some of her activities
include:
In 1996, she co-founded Protagen AG (https://protagen.com/)
in Dortmund, including with Prof. Helmut Meyer, as a
spin-out of the Max-Planck-Institute to
commercialize her discoveries.
�
Protagen Protein
Services (https://protagenproteinservices.com/)
a 2014 spin-off company of Protagen delivers expert
protein, antibody, proteomics & peptide contract
services to the pharmaceutical industry & health
care sectors.
�
Both companies have
advanced these technologies & applications; Protagen
has screened and profiled the autoantibody
repertoire of over 20,000 patients (https://protagen.com/data-and-insight...).
�
Protagen AG and
Protagen Protein Services have over 200 employees in
2018. Since 2016, Prof. Cahill is a shareholder &
Advisory Board member of Atturos Ltd, Prof. Stephen
Pennington's UCD spin-out company involved in
improved Prostate Cancer diagnosis (http://atturos.com/
and
http://atturos.com/company/advisors/).
�
�
She received her
Honors degree in Molecular Genetics from Trinity
College Dublin (1989) and her PhD in Immunology from
Dublin City University (1994).
�
While studying in
Trinity, she was awarded the Irish American
Fellowship Prize (1988) to research at Prof.
Pringle's laboratory in the University of Michigan,
Ann Arbor, USA.
�
During her
undergraduate & PhD studies, she worked, including
as Assistant Manager, in fine-dining Country Clubs
in Long Island, New York (4 summers) & in Tenafly,
New Jersey (4 summers).
�
On obtaining her PhD,
she obtained an EU 'Human Capital & Mobility'
Post-doctoral Fellowship at the Technical
University, Munich, Germany (1994-1995).
�
Prof. Cahill became
Group Leader of the Protein Technology Group in the
Max-Planck-Institute of Molecular Genetics, Berlin
(1996-2003).
�
She obtained an
Associate Professor position, in the Department of
Clinical Pharmacology and Director of Proteomics
Core, RCSI, Dublin (2000-2005).
�
Since 2005 - present,
she is Full Professor of Translational Science in
the School of Medicine, University College Dublin
and she has extensive management experience,
including successfully obtaining funding from the
European Commission (FP4, FP5, FP6, FP7 and Horizon
2020), Science Foundation Ireland, Enterprise
Ireland, Health Research Board & successfully
writing, project managing, publishing & reporting on
all financial & regulatory aspects in academic &
private sectors, in the companies she co-founded.
She has over 100 peer reviewed publications, with
over 5000 citations and a H-index is 31, which is in
the top 10% globally for the Biomedicine discipline.
�
Prof. Cahill is
internationally recognized for her biomedical
research, publications and patent record in life
sciences, biotechnology, personalized healthcare,
personalized medicine, diagnostics, biomarker
discovery and validation, proteomics, biotechnology,
high content protein and antibody arrays and their
biomedical, diagnostic and clinical applications.
�
Her publications have
demonstrated utility and applications in the
research, commercial & clinical sectors and include
characterization of antibodies specificity
(including therapeutic antibodies), biomarker
discovery, diagnostics, assay development,
protein-interaction studies, proteomics, large
scale/systems biology research, validating biomarker
panels in diagnostic clinical trial, personalized
medicine and assessing immune related adverse
events.
She has given over 100 Keynotes Lectures in Ireland,
UK, Europe, USA, China, Japan, South Korea,
Australia, South America.
�
For example, she is
invited to the '5th Precision Medicine and
Biomarkers Leaders' Summit' in Munich in September
2018 & will Chair a Roundtable on Personalized
Medicine and Adverse Events to discuss whether
lessons can be learned from cancer immunotherapy and
immune related adverse events to provide insight
into understanding adverse events and personalized
medicine and finding adverse event predictive
biomarkers
